According to Gram Research analysis of a 2026 randomized controlled trial of 153 adults, intranasal vitamin B12 spray works just as well as muscle injections and IV infusions for treating B12 deficiency anemia over 28 days. All three delivery methods equally improved hemoglobin levels and red blood cell size, making the nasal spray a proven, needle-free alternative for patients who prefer it or lack easy access to medical clinics.
A new study compared three ways to treat vitamin B12 deficiency anemia: a nasal spray, a shot in the muscle, and an IV infusion. Researchers tracked 153 patients for 28 days and found that all three methods helped patients recover equally well. The nasal spray was just as effective as the traditional muscle injection and the IV treatment, making it a promising option for people who don’t like needles or live in areas with limited medical resources. This finding could change how doctors treat this common blood condition.
Key Statistics
A 2026 randomized controlled trial of 153 adults found that intranasal vitamin B12 spray produced equivalent hemoglobin recovery compared to intramuscular injection and intravenous infusion over 28 days, with no statistically significant differences between the three routes.
In the same trial, intramuscular injection produced a stronger reticulocyte response (young red blood cell release) compared to intranasal and intravenous routes, though this didn’t result in better overall hemoglobin recovery.
Gram Research analysis shows that baseline hemoglobin level, vegan diet status, and age were independent predictors of B12 treatment response, accounting for 57.5% of variation in outcomes across all three delivery methods.
The 2026 trial found that parenteral routes (muscle injection and IV infusion) normalized lactate dehydrogenase more effectively than intranasal spray, though all three methods significantly improved this marker of cell damage.
The Quick Take
- What they studied: Whether three different ways of giving vitamin B12 (nasal spray, muscle shot, and IV infusion) work equally well to treat anemia caused by B12 deficiency
- Who participated: 153 adults with vitamin B12 deficiency anemia, divided into three groups: 55 received nasal spray, 56 received IV infusion, and 42 received muscle injections
- Key finding: All three delivery methods improved blood health equally well over 28 days, with no meaningful differences in how much hemoglobin (the protein that carries oxygen) increased
- What it means for you: If you have B12 deficiency anemia, the nasal spray is now a proven alternative to needles, especially helpful if you’re uncomfortable with injections or live far from medical clinics. However, this study only tracked short-term results, so long-term effectiveness needs more research.
The Research Details
This was a randomized controlled trial, which is the gold standard for medical research. Researchers randomly assigned 153 adults with B12 deficiency anemia into three equal groups. One group received B12 as a nasal spray, another as an injection into the muscle, and the third as an IV infusion into the bloodstream. Researchers measured blood health markers (hemoglobin, red blood cell size, and other indicators) at the start and then on days 7, 14, and 28 to track recovery.
The study used sophisticated statistical methods to compare the three groups fairly. They looked at raw differences between groups and also adjusted for factors like age, diet, and starting hemoglobin levels that might affect how well treatment worked. This approach helps isolate the true effect of the delivery method itself.
Comparing different delivery methods directly in a controlled setting is crucial because real-world practice often relies on tradition rather than evidence. The muscle injection has been the standard treatment for decades, but newer options like nasal spray might be more convenient. This rigorous comparison provides doctors with solid evidence to offer patients better choices based on their preferences and circumstances.
This study has several strengths: it’s a randomized controlled trial (the highest quality study design), it tracked patients over time with multiple measurements, it used appropriate statistical tests, and it was registered in a clinical trial database before starting. The sample size of 153 is reasonable for this type of research. One limitation is that the study only followed patients for 28 days, so we don’t know if the nasal spray works as well for long-term maintenance therapy.
What the Results Show
All three treatment methods significantly improved hemoglobin levels (the main measure of anemia recovery) by day 28, with no statistically significant differences between groups. This means a patient receiving nasal spray recovered just as well as someone getting a muscle injection or IV infusion.
The study also measured mean corpuscular volume (MCV), which reflects red blood cell size. In B12 deficiency, red blood cells become abnormally large, and treatment should shrink them back to normal. All three routes reduced MCV equally well, with no meaningful differences between groups.
When researchers adjusted their analysis for factors like age, starting hemoglobin level, and diet type, the three routes still showed equivalent effectiveness. This means the delivery method itself—not other patient factors—was equally effective across all three approaches.
The intramuscular injection produced a stronger reticulocyte response (an increase in young red blood cells being released into the bloodstream), suggesting it may stimulate bone marrow slightly more aggressively. However, this didn’t translate to better overall hemoglobin recovery. The parenteral routes (muscle injection and IV) normalized lactate dehydrogenase (an enzyme that indicates cell damage) more effectively than the nasal spray, though all three routes improved this marker. Baseline hemoglobin level, vegan diet status, and age were independent predictors of treatment response, meaning these factors influenced how well patients recovered regardless of which delivery method they received.
Previous research has mostly focused on the muscle injection as the standard treatment, with limited head-to-head comparisons of alternative routes. This study fills an important gap by directly comparing all three methods in a rigorous way. Earlier studies suggested nasal spray might work, but they weren’t as thorough or well-controlled. This research provides the strongest evidence to date that nasal spray is truly equivalent to traditional methods for short-term recovery.
The most important limitation is that the study only tracked patients for 28 days. We don’t know if the nasal spray maintains effectiveness over months or years of regular use, which is how many patients actually receive B12 therapy. The study also didn’t measure patient satisfaction, convenience, or side effects in detail, which matter for real-world treatment decisions. Additionally, the findings apply specifically to adults with B12 deficiency anemia and may not apply to other conditions or populations. The study was conducted in a single healthcare system, so results may vary in different settings or countries.
The Bottom Line
For adults with B12 deficiency anemia, the nasal spray is now an evidence-based alternative to muscle injections and IV infusions for initial treatment (high confidence for 28-day outcomes). Choose based on your preferences: nasal spray if you dislike needles, muscle injection if you prefer traditional treatment, or IV if you need rapid administration in a clinical setting. For long-term maintenance beyond 28 days, discuss options with your doctor since this study didn’t evaluate extended use (moderate confidence).
This research matters most for people with diagnosed B12 deficiency anemia who want options beyond needles, people in rural or resource-limited areas where clinic visits are difficult, and healthcare providers looking for evidence-based alternatives. It’s less relevant for people without B12 deficiency or those with other types of anemia. Vegans and older adults should know they may need closer monitoring based on this study’s findings.
Most patients showed significant improvement within 7-14 days, with full recovery by 28 days across all three methods. However, this timeline applies to initial treatment only. For long-term maintenance therapy, you’ll need to discuss a personalized schedule with your doctor, as this study didn’t evaluate repeated doses over months or years.
Frequently Asked Questions
Is B12 nasal spray as effective as B12 shots for anemia?
Yes, according to a 2026 trial of 153 patients, intranasal B12 spray produced equivalent hemoglobin recovery compared to muscle injections and IV infusions over 28 days. All three methods worked equally well for short-term treatment of B12 deficiency anemia.
How long does it take for B12 treatment to work?
Most patients showed significant improvement within 7-14 days, with full hemoglobin recovery by 28 days across all three delivery methods (nasal spray, injection, and IV). Individual timelines vary based on starting hemoglobin level and age.
Can I use B12 nasal spray long-term instead of shots?
The 2026 trial only tracked 28-day outcomes, so long-term effectiveness of nasal spray for maintenance therapy remains unclear. Discuss extended use options with your doctor, as this study didn’t evaluate repeated doses over months or years.
Who should not use the B12 nasal spray?
This study focused on adults with B12 deficiency anemia, so findings may not apply to children, pregnant women, or people with other conditions. Consult your doctor about whether nasal spray is appropriate for your specific situation.
Does diet affect how well B12 treatment works?
Yes, the 2026 trial found that vegan diet status independently predicted treatment response, meaning vegans may recover differently than non-vegans. Age and starting hemoglobin level also influenced how well patients responded to B12 therapy.
Want to Apply This Research?
- Log your hemoglobin levels and B12 treatment dates weekly for the first month, then monthly thereafter. Track any symptoms like fatigue, shortness of breath, or tingling that improve with treatment to measure real-world impact beyond lab numbers.
- Set reminders for your B12 therapy schedule (whether nasal spray, injection, or IV). If using nasal spray, establish a consistent time and technique daily. If using injections, schedule appointments in advance and track injection sites to rotate them properly.
- Use the app to record blood test results (hemoglobin, MCV, B12 levels) at baseline and after 28 days to compare your personal recovery to the study results. Continue tracking every 3-6 months during maintenance therapy to catch any decline early and adjust treatment as needed.
This research summary is for educational purposes and should not replace professional medical advice. The findings apply specifically to short-term treatment (28 days) of B12 deficiency anemia in adults. If you have or suspect B12 deficiency anemia, consult your healthcare provider for diagnosis, treatment recommendations, and monitoring appropriate for your individual situation. Do not start, stop, or change B12 therapy without medical guidance. This study did not evaluate long-term maintenance therapy, so discuss extended treatment plans with your doctor.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.